10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q/A

(Amendment No. 1)

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2013

Or

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from ________________________

Commission file number: 000-53404

Bio-Path Holdings, Inc.

(Exact name of registrant as specified in its charter)

Utah	87-0652870
(State or other jurisdiction of	(I.R.S. employer
incorporation or organization)	identification no.)

2626 South Loop, Suite 180, Houston, TX 77054

(Address of principal executive offices)

Registrant's telephone no., including area code: (832) 971 -6616

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes      x      No      ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).  Yes      x      No      ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.  See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer  ¨	Accelerated filer  ¨
Non-accelerated filer    ¨  (Do not check if a smaller reporting company)	Smaller reporting company  x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes      ¨      No      x

At November 12, 2013, the Company had 84,237,872 outstanding shares of common stock, no par value.

EXPLANATORY NOTE

Bio-Path Holdings, Inc. (the “Company”) is filing this Amendment No. 1 to its Quarterly Report on Form 10-Q for the quarter ended September 30, 2013, filed with the Securities and Exchange Commission on November 14, 2013 (“Form 10-Q”), for the sole purpose of furnishing the interactive data files marked as Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB and 101.PRE and formatted in XBRL (eXtensible Business Reporting Language).

No other changes have been made to the Form 10-Q. This Amendment No. 1 speaks only as of the original filing date of the Form 10-Q, does not reflect events that may have occurred subsequent to such original filing date and does not modify or update in any way disclosures made in the Form 10-Q.

PART III

ITEM 6.  EXHIBITS

Exhibit No.	Description of Exhibit
31*	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 302 of the Sarbanes Oxley Act of 2002.
32*	Certification of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes Oxley Act of 2002.
99.1*	Temporary Hardship Exemption
101.INS**	XBRL Instance Document
101.SCH**	XBRL Taxonomy Schema Document
101.CAL**	XBRL Taxonomy Calculation Linkbase Document
101.DEF**	XBRL Taxonomy Definition Linkbase Document
101.LAB**	XBRL Taxonomy Label Linkbase Document
101.PRE**	XBRL Taxonomy Presentation Linkbase Document

* Previously filed as an exhibit to the Form 10-Q.

** Filed herewith. Pursuant to Rule 406T of Regulation S-T, the interactive data files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections.  

SIGNATURE

In accordance with the requirements of the Exchange Act, the Company has caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Dated: November 18, 2013	BIO-PATH HOLDINGS, INC.
	By	/s/ Peter H. Nielsen
		Chief Executive Officer, President/Principal Executive
		Officer, Chief Financial Officer, Principal Financial Officer

XML

Commitments and Contingencies

9 Months Ended

Sep. 30, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

10. Commitments and Contingencies

Technology License – Related Party - The Company has negotiated exclusive licenses from the MD Anderson Cancer Center to develop drug delivery technology for antisense and siRNA drug products. These licenses require, among other things, the Company to reimburse MD Anderson for ongoing patent expense. Related party accrued license payments attributable to the Technology License totaling $50,000 are included in Current Liabilities as of September 30, 2013. Related party accrued expense totaling $52,050 as of September 30, 2013 represents hospital costs for the clinical trial and are not related to the Technology License. As of September 30, 2013, the Company estimates reimbursable past patent expenses will total approximately $75,000 for the Technology License. The Company will be required to pay when invoiced the past patent expenses at the rate of $25,000 per quarter. In addition, the Company decided to discontinue development of its siRNA technology and subsequently canceled its siRNA license in June of 2012 (See Note 1).

Drug Supplier Project Plan - In August of 2012, Bio-Path entered into two project plan agreements with the Company’s drug substance manufacturer and its final drug product manufacturer for the manufacture and delivery of final drug product incorporating the drug substance for expected delivery in the fourth quarter of 2012, with delivery subsequently revised to the first quarter of 2013. The project plans required the Company to pay approximately $340,000 in various stages as the drug substance and product are manufactured and delivered to the Company. Of this amount, $195,000 was paid for or owed by the Company and was carried on the Balance Sheet as of December 31, 2012 as Prepaid Drug Product for Testing. The drug product was delivered to the Company in the first quarter of 2013 and the Balance Sheet item Prepaid Drug Product for Testing totaling $195,000 was expensed in the first quarter 2013. Amounts owed to the Company’s manufacturers for this drug batch have been paid subsequent to year end. The Company signed a supply agreement in the third quarter of 2013. Installment payments paid or in accounts payable to the Company’s drug manufacturers totaling $148,301 are being carried at cost on the Balance Sheet as of September 30, 2013 as Prepaid Drug Product for testing.

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended				9 Months Ended				77 Months Ended
	Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013		Sep. 30, 2012		Sep. 30, 2013
Revenue	$ 0		$ 0		$ 0		$ 0		$ 0
Operating expense
General & administrative	810,152	[1]	246,086	[1]	1,290,506	[1]	729,569	[1]	8,349,969	[1]
Total operating expense	1,393,728		840,489		2,478,284		2,150,898		14,926,964
Net operating loss	(1,393,728)		(840,489)		(2,478,284)		(2,150,898)		(14,926,964)
Other income (expense)
Interest income	837		26		2,492		768		79,581
Other income	0		0		0		0		244,479
Other expense	(316)		(89)		(661)		(487)		(4,834)
Total Other Income (Expense)	521		(63)		1,831		281		319,226
Net Loss	(1,393,207)		(840,552)		(2,476,453)		(2,150,617)		(14,607,738)
Loss per share
Net loss per share, basic and diluted	$ (0.02)		$ (0.01)		$ (0.04)		$ (0.04)		$ (0.30)
Basic and diluted weighted average number of common shares outstanding	75,380,214		58,902,046		68,068,456		58,717,393		48,619,280
All Other
Operating expense
Research and development	568,576	[2]	546,821	[2]	1,125,711	[2]	994,459	[2]	5,451,308	[2]
MD Anderson for License
Operating expense
Research and development	$ 15,000	[3]	$ 47,582	[3]	$ 62,067	[3]	$ 426,870	[3]	$ 1,125,687	[3]

[1] General & administrative expense includes stock for services, stock option and warrant expenses of $599,424 for the quarter ending 9/30/2013; $609,347 and $3,250 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and for the period from inception through 9/30/2013 $3,200,103 for stock option and warrant expense and $318,500 in stock for services.

[2] Research and development expense includes stock option expenses of $6,623 and $11,414 for the quarters ending 9/30/2013 and 9/30/2012, respectively; $26,256 and $42,231 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and $449,255 for the period from inception through 9/30/2013. Research and development expense also includes amortization expenses of $40,156 and $48,503 for the quarters ending 9/30/2013 and 9/30/2012, respectively; $120,469 and $145,115 for the nine month periods ending 9/30/2013 and 9/30/2012, respectively; and $1,097,203 for the period from inception through 9/30/2013.

[3] Includes $345,000 technology impairment charge for the nine month period ending 9/30/2012; and $690,000 for the period from inception through 9/30/2013

XML

Prepaid Drug Product for Testing

9 Months Ended

Sep. 30, 2013

Prepaid Drug Product For Testing [Abstract]

Prepaid Drug Product for Testing

3. Prepaid Drug Product for Testing

Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future R&D activities are deferred and capitalized. Such amounts will be recognized as an expense as the related goods are delivered or the related services are performed. The Company incurred installments to its contract drug manufacturing and raw material suppliers totaling $195,000 during 2012 pursuant to a Drug Supply Contract (See Note 10.) for the manufacture and delivery of the Company’s lead drug product for testing in a Phase I clinical trial. This amount was carried on the Balance Sheet as of December 31, 2012 at cost as Prepaid Drug Product for Testing. This product was delivered to the Company in the first quarter of 2013 and costs associated with this drug batch were expensed. Another drug batch was in the process of starting to be produced in the third quarter of 2013 and installment costs totaling $148,301 are carried on the Balance Sheet as of September 30, 2013 as Prepaid Drug Product for Testing (See Note 10.).

XML

Accrued License Payments - Related Party - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Related Party Transaction [Line Items]
Accrued license payments - related party	$ 50,000	$ 100,000

XML

Subsequent Events

9 Months Ended

Sep. 30, 2013

Subsequent Events [Abstract]

Subsequent Events

11. Subsequent Events

Subsequent to September 30, 2013, the Company is committed to issue 8,052,416 shares of common stock pursuant to the private placement disclosed in Note 8.  In connection with this private placement, the Company is also committed to issue 805,242 shares of common stock to the  Placement Agent as commission for the shares of common stock sold to investors.   

On November 5, 2013, the Company filed a registration statement on Form S-3 with the SEC, which has not yet been declared effective. The shelf registration statement has been filed to register the offering and sale of up to $100 million of our common stock, preferred stock, warrants to purchase common stock or preferred stock or any combination thereof, either individually or in units. The foregoing does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. There can be no assurance that the shelf registration statement will be declared effective.

XML

Stock Options and Warrants - Additional Information (Detail) (USD $)	1 Months Ended
	Aug. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation arrangement by share based payment award options grants in period	2,500,000
Share based compensation arrangement by share based payment award award vesting period	3 years
Share based compensation arrangements by share based payment award options grants in period weighted average exercise price	$ 0.46
Share based compensation arrangement by share based payment award options grants in period grant date fair value	$ 1,125,000
Share based compensation arrangement by share based payment award average annual volitality rate	189.00%
Percentage of stock options vested on the grant date, stock options issued	50.00%
Percentage of stock options vested	50.00%

XML

Stockholders' Equity - Additional Information (Detail) (USD $)	1 Months Ended			2 Months Ended	3 Months Ended		9 Months Ended		77 Months Ended	2 Months Ended	1 Months Ended					2 Months Ended	1 Months Ended																			6 Months Ended		1 Months Ended											6 Months Ended	1 Months Ended
	Aug. 31, 2012	Oct. 31, 2011	Apr. 30, 2008	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	May 31, 2013 IPO	Jun. 30, 2010 Warrant	Sep. 30, 2013 Private Placement memorandum	Aug. 31, 2013 Private Placement memorandum	Jun. 30, 2012 Private Placement memorandum	Jun. 30, 2009 Private Placement memorandum	May 31, 2013 Private Placement memorandum	Dec. 31, 2008 Investor Relations Services	Jun. 30, 2010 LPC	Jun. 30, 2007 Founders	Mar. 31, 2012 Equity Unit Purchase Agreements LPC	Dec. 31, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2011 Equity Unit Purchase Agreements LPC	Jun. 30, 2011 Equity Unit Purchase Agreements LPC	Nov. 30, 2010 Equity Unit Purchase Agreements LPC	Oct. 31, 2010 Equity Unit Purchase Agreements LPC	Sep. 30, 2010 Equity Unit Purchase Agreements LPC	Jul. 31, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Minimum	Jun. 30, 2010 Equity Unit Purchase Agreements LPC Maximum	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 1	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 2	Apr. 30, 2012 Equity Unit Purchase Agreements LPC Scenario 3	Jun. 30, 2010 LPC financing agreement LPC	Jun. 30, 2011 Investors	Jun. 30, 2013 Investors	Dec. 31, 2012 Investors	Apr. 30, 2011 Investors Private Placement memorandum	May 31, 2010 Investors Private Placement memorandum	Jan. 31, 2010 Investors Private Placement memorandum	Dec. 31, 2009 Investors Private Placement memorandum	Nov. 30, 2009 Investors Private Placement memorandum	Jun. 30, 2009 Investors Private Placement memorandum	Aug. 31, 2007 Investors Private Placement memorandum	Aug. 31, 2007 Investors Additional Shares	Jan. 31, 2010 Investors Additional Shares Private Placement memorandum	Jun. 30, 2011 Placement Agent	Aug. 31, 2007 Placement Agent	Jun. 30, 2013 Placement Agent	May 31, 2010 Placement Agent Private Placement memorandum	Jan. 31, 2010 Placement Agent Private Placement memorandum	Jun. 30, 2009 Placement Agent Private Placement memorandum	Nov. 30, 2007 MD Anderson Cancer Center	Apr. 30, 2008 BioPathHoldingsInc	Feb. 29, 2008 BioPathHoldingsInc	Feb. 29, 2008 Ogden Golf Co.
Shareholders Equity [Line Items]
Common stock and warrants issued, shares											571,429								6,505,994	166,667	172,414	83,333	164,853	135,135	135,135	125,000	375,000	571,429			89,286	96,154	185,185	12,000		11,664,665								3,975,000	1,333,334			530,833	1,496,499	78,000	360,000	66,000		200,000	80,000
Common stock issued , value										$ 489,501									$ 6,506																			$ 1,794,205						$ 993,750	$ 1,000,000
Common stock issued , shares	50,000													150,000																					5,980,685												598,069						3,138,889
Common stock issued merger transactions, shares																																																							38,023,578
Common stock retained shareholders, shares																																																								3,600,000
Common stock issued for services, value	18,500		180,000											18,500			40,000
Common stock issued, additional shares			24
Common stock issued for service, shares																	100,000
Common stock and warrant issued, shares															660,000																								780,000	2,700,000						900,000
Common stock repurchased, shares																																							780,000	2,700,000			660,000			900,000
Common stock and warrants issued, Value																																							273,000		675,000	675,000	165,000			225,000
Warrants exercisable period																																							2 years	2 years			2 years			2 years
Warrants exercise price																												$ 1.50											$ 1.50	$ 1.50			$ 1.50			$ 1.50
Equity purchase agreement value																		7,000,000											50,000	1,000,000
Agreement period																												24 months
Proceeds from issuance of common stock and warrant from LPC							5,403,106	973,146	13,442,489											50,000	50,000	25,000	50,000	50,000	50,000	50,000	150,000	200,000			25,000	25,000	50,000
Committed shares issued																				2,084	2,084	1,042	2,084	2,084	2,084	2,084	6,251				1,042	1,042	2,084	566,801
Warrants issued, shares																				0	0	0	0	0	0	0	0
Common stock issued for exercise of warrant (in shares)		1,920,000
Common stock issued for exercise of warrant		576,000
Common stock issued for services				$ 346,201	$ 708,600	$ 795,001	$ 0	$ 18,500	$ 318,500			$ 3,220,966	$ 3,220,966			$ 2,000,198
Common Stock, shares issued					62,219,050		75,380,214		75,380,214																												3,300,337
Common Stock, shares outstanding					62,219,050		75,380,214		75,380,214
Preferred Stock, shares outstanding					0		0		0

XML

Additional Paid In Capital For Shares To Be Issued - Additional Information (Detail) (USD $)	Sep. 30, 2013		Dec. 31, 2012
Additional Paid In Capital For Shares To Be Issued [Line Items]
Common stock issuable shares issuable	8,052,416		2,541,700
Other Additional Capital	$ 3,220,967	[1]	$ 762,510	[2]

[1] Represents 8,052,416 shares of common stock

[2] Represents 2,541,700 shares of common stock

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended		77 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013
CASH FLOW FROM OPERATING ACTIVITIES
Net loss	$ (2,476,453)	$ (2,150,617)	$ (14,607,738)
Adjustments to reconcile net loss to net cash used in operating activities
Amortization	120,469	145,115	1,097,203
Technology impairment	0	345,000	690,000
Common stock issued for services	0	18,500	318,500
Stock options and warrants	635,603	45,481	3,649,357
(Increase) decrease in assets
Prepaid drug product for testing	46,699	73,500	(148,301)
Other current assets	(7,138)	3,044	(49,713)
Increase (decrease) in liabilities
Accounts payable and accrued expenses	(155,491)	(47,559)	173,753
Net cash used in operating activities	(1,836,311)	(1,567,536)	(8,876,939)
CASH FLOW FROM INVESTING ACTIVITIES
Purchase of exclusive license - related party	0	(25,000)	(884,710)
Net cash used in investing activities	0	(25,000)	(884,710)
CASH FLOW FROM FINANCING ACTIVITIES
Proceeds from convertible notes	0	0	435,000
Cash repayment of convertible notes	0	0	(15,000)
Net proceeds from sale of common stock	5,403,106	973,146	13,442,489
Net cash from financing activities	5,403,106	973,146	13,862,490
NET INCREASE (DECREASE) IN CASH	3,566,795	(619,390)	4,100,841
Cash, beginning of period	534,046	952,252	0
Cash, end of period	4,100,841	332,862	4,100,841
Cash paid for
Interest	0	0	445
Income taxes	0	0	0
Non-cash financing activities
Common stock issued upon conversion of convertible notes	0	0	420,000
Placement Agent
Non-cash financing activities
Common stock issued	448,950	0	1,040,516
MD Anderson for License
Non-cash financing activities
Common stock issued	0	0	2,354,167
LPC
Non-cash financing activities
Common stock issued	$ 0	$ 0	$ 210,755

XML

Organization and Business

9 Months Ended

Sep. 30, 2013

Organization and Business [Abstract]

Organization and Business

1. Organization and Business

Bio-Path is a development stage company with its lead cancer drug candidate, Liposomal Grb-2 (L-Grb-2 or BP-100-1.01), currently in clinical trials. The Company was founded with technology from The University of Texas, MD Anderson Cancer Center (“MD Anderson”) and is dedicated to developing novel cancer drugs under an exclusive license arrangement. The Company has drug delivery platform technology with composition of matter intellectual property for systemic delivery of antisense. Bio-Path also plans to investigate developing liposome tumor targeting technology, which has the potential to be developed to augment the Company’s current delivery technology to improve further the effectiveness of its antisense. In addition to its existing technology under license, the Company expects to maintain a close working relationship with key members of the MD Anderson staff, which has the potential to provide Bio-Path with additional drug candidates in the future. Bio-Path also expects to broaden its technology to include cancer drugs other than antisense, including drug candidates licensed from institutions other than MD Anderson.

Bio-Path believes that its core technology, if successful, will enable it to be at the center of emerging genetic and molecular target-based therapeutics that require systemic delivery of DNA and RNA-like material. The Company’s two lead liposomal antisense drug candidates are targeted to treat acute myeloid leukemia, myelodysplastic syndrome, chronic myelogenous leukemia, acute lymphoblastic leukemia and follicular lymphoma, and if successful, could potentially be used in treating many other indications of cancer. For example, recently in July of 2013 Bio-Path announced that it was initiating development of its lead cancer drug Liposomal Grb-2 to treat triple negative breast cancer (TNBC) and inflammatory breast cancer (IBC), two cancers characterized by formation of aggressive tumors and relatively high mortality rates.

Bio-Path is currently treating patients with its lead cancer drug candidate Liposomal Grb-2 in a Phase I clinical trial. In March of 2010, Bio-Path received written notification from the U.S. Food and Drug Administration (the “FDA”) that its application for Investigational New Drug (“IND”) status for L-Grb-2 had been granted. This enabled the Company to commence its Phase I clinical trial to study L-Grb-2 in human patients, which began in the third quarter 2010.

The Phase I clinical trial is a dose-escalating study to determine the safety and tolerance of escalating doses of L-Grb-2. The study will also determine the optimal biologically active dose for further development. The pharmacokinetics of L-Grb-2 in patients will be studied, making it possible to investigate whether the delivery technology performs as expected based on pre-clinical studies in animals. In addition, patient blood samples from the trial will be tested using a new assay developed by the Company to measure down-regulation of the target protein, the critical scientific data that will demonstrate that the delivery technology does in fact successfully deliver the antisense drug substance to the cell and across the cell membrane into the interior of the cell where expression of the target protein is blocked. The clinical trial is being conducted at The University of Texas MD Anderson Cancer Center.

The original IND granted by the FDA in March of 2010 allowed the Company to proceed with a Phase I clinical trial having five (5) cohorts culminating in a maximum dose of 50 mg/m². However, in November of 2012, the Company announced that since there had been no evidence of significant toxicity from treatment of patients with L-Grb-2, the Company was proceeding with requesting the FDA to allow higher dosing in patients. The Principal Investigator for the clinical trial, in consultation with Bio-Path’s Board of Directors, advised that with the absence of any real toxicity barriers, the Company should continue to evaluate higher doses of Liposomal Grb-2. The absence of significant toxicity provides a significant opportunity for the Company to test higher doses in patients in order to find a dose that provides maximum potential benefit and duration of anti-leukemia effect. These actions were approved and a revised protocol is in place allowing higher dosing. The Company announced in June of 2013 that it completed Cohort 5, successfully treating three patients at a dose 60 mg/m², which had been increased from 50 mg/m²in the revised protocol. The Company has enrolled three patients in Cohort 6 for treatment at a dose of 90 mg/m² and currently has two evaluable patients. The Company is currently awaiting drug resupply to complete Cohort 6.

Patients eligible for enrollment into the Phase I clinical trial have refractory or relapsed Acute Myeloid Leukemia (AML), Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS) and who have failed other approved treatments. These are patients with very advanced stages of the disease, and consequently, not all patients enrolled are able to complete the four-week treatment cycle because of progressive disease, which is unrelated to the treatment with Liposomal-Grb-2.

An important outcome for the Phase I clinical trial is the ability to assess for the first time the performance of the Company’s delivery technology platform in human patients. The Company has developed two new assays to be able to provide scientific proof of concept of the delivery technology. The first involves a novel detection method for the drug substance in blood samples that will be used to assess the pharmacokinetics of the drug. The second involves a method to measure down-regulation of the target protein in a patient blood sample that was achieved. The latter measurement will provide critical proof that the neutral liposome delivery technology delivered the drug substance to the cell and was able to transport it across the cell membrane into the interior to block cellular production of the Grb-2 protein.

In this regard, in August of 2013 Bio-Path announced that its liposomal delivery technology achieved a major milestone in the development of antisense therapeutics based on a scientific assay confirming that treating patients with its drug candidate BP-100-1.01 inhibits the Grb-2 disease-causing target protein in patients with blood cancers. Inhibition of the disease-causing protein has the effect of down regulating the disease. This will allow for Liposomal Grb-2 to be used potentially in combination with current frontline treatments. This discovery also points to the potential use of a liposomal antisense treatment as a standalone treatment to transform and manage a disease, which has a disease causing protein, as a chronic disorder. This accomplishment is potentially a significant breakthrough for antisense therapeutics, whose development, to date, as a class of therapeutics has been severely limited by a lack of a systemic delivery mechanism that can safely distribute the drug throughout the body and get the antisense drug substance across the cell membrane into the interior of the cell. Further, we expect that scientific proof of principal for our delivery technology may lead to licensing and business development opportunities, furthering our business model.

Being platform technology, a successful demonstration of the delivery technology in this study will allow the Company to begin expanding Bio-Path’s drug candidates by simply applying the delivery technology template to multiple new drug product targets. In this manner, Bio-Path can quickly build an attractive drug product pipeline with multiple drug product candidates for treating cancer as well as treating other important diseases including diabetes, cardiovascular conditions and neuromuscular disorders. Currently, the Company is researching potential targets for which it can apply its liposomal antisense drug delivery technology.

The Phase I clinical trial is typically ended when a maximum tolerated dose (MTD) is encountered. However, due to the lack of toxicity of the drug to date, it is not expected that a MTD will be encountered. As a result, the optimal biological dose will be determined and this dose will be used in the following Phase II clinical trial. The Company plans to evaluate patients at the close of Cohort 6 to evaluate whether the Phase I clinical trial should be ended at that time. It is expected that the down regulation assay will be a factor in the evaluation of whether we have reached optimal inhibition. It is noted, however, that the lack of toxicity is a major advantage for the drug candidate BP-100-1.01 since it allows higher levels of drug to be administered to the patient, increasing the potential therapeutic benefit.

Bio-Path has also been working with the Principal Investigator to finalize plans for Phase II clinical trials in Liposomal Grb-2. Significantly, these plans include three Phase II trials, one each for CML, AML and MDS, of the drug candidate Liposomal Grb-2 in salvage therapy for very advanced patients.

At the end of January 2012, the Company’s Board of Directors held a strategic planning session. Among several topics was a discussion of Company’s liposomal siRNA technology. The siRNA discussion covered a broad range of topics including intellectual property, the amount of development that would be needed and the overall impression of diminishing acceptance of siRNA technology by the pharmaceutical industry and equity market investors. The Board compared this to our core liposomal antisense technology, which has a stronger intellectual property position, a method of action blocking expression of disease-causing proteins that is better understood in the scientific community and a much easier path for development than liposomal siRNA technology. Since both antisense and siRNA are means to block expression of disease-causing proteins, the Board concluded that there was no apparent reason to develop a second, higher-risk siRNA method of blocking protein expression when the development of the liposomal antisense method is now much further along and showing promising results. After this discussion the Board decided to discontinue development of the licensed liposomal siRNA technology and the Company commenced discussions regarding this decision with MD Anderson to determine with them whether to modify the license to include other products, postpone the license or simply abandon the license. As an interim step pending final resolution of this matter, the Company took a charge of $345,000 at the end of the fiscal year ending December 31, 2011 to reduce the carrying value of the siRNA license by fifty percent (50%). This amount represented one half of the value of the common stock given to MD Anderson when the original siRNA license was finalized. In June 2012, the Company decided to write-off the balance of the carrying value of the siRNA license, representing $345,000, and cancel the license.

The Principal Investigator for the Phase I clinical trial, Dr. Jorge Cortes (the “Principal Investigator”), is a leading expert in the treatment of CML, AML, MDS and ALL. In the continuing effort to keep the leukemia oncology community apprised of the development of Liposomal Grb-2, the Principal Investigator submitted an abstract to the American Society of Hematology (ASH) to be considered for presentation at ASH’s annual meeting in December of 2013. The abstract was accepted and a poster updating the progress in the Phase I clinical trial will be presented at the ASH annual meeting. A major part of the update on the Liposomal Grb-2 Phase I trial will be the inclusion of the results of testing of patient blood samples, which demonstrates significant inhibition of the disease causing protein Grb-2. This is a significant development which suggests the potential of Liposomal Grb-2 to inhibit AML and MDS in patients.

The Company was founded in May of 2007 as a Utah corporation. In February of 2008, Bio-Path completed a reverse merger with Ogden Golf Co. Corporation, a public company traded over the counter that had no current operations. The name of Ogden Golf was changed to Bio-Path Holdings, Inc. and the directors and officers of Bio-Path, Inc. became the directors and officers of Bio-Path Holdings, Inc. Bio-Path has become a publicly traded company (symbol OTCBB: BPTH) as a result of this merger. The Company’s operations to date have been limited to organizing and staffing the Company, acquiring, developing and securing its technology and undertaking product development for a limited number of product candidates including readying and now conducting a Phase I clinical trial in its lead drug product candidate Liposomal Grb-2.

An important milestone was achieved for the Company in the second quarter, 2012 when Bio-Path’s common stock began trading on the quality-controlled OTCQX. OTCQX is the highest tier, premier trading platform for OTC companies. The Company also announced that it had retained Roth Capital Partners to serve as the Company’s Designated Advisor for Disclosure (“DAD”) on OTCQX, responsible for providing guidance on OTCQX requirements.

As of September 30, 2013, Bio-Path had $4,100,841 in cash on hand. During the third quarter of 2013, the Company received approximately $2.8 million in cash net of placement agent commissions from the sale of shares of common stock in a private placement.

As the Company has not begun its planned principal operations of commercializing a product candidate, the accompanying financial statements have been prepared in accordance with principles established for development stage enterprises.

XML

Accounts Payable

9 Months Ended

Sep. 30, 2013

Accounts Payable Disclosure [Abstract]

Accounts Payable

4.Accounts Payable

As of September 30, 2013, Current Liabilities included accounts payable of $43,578 comprised primarily of approximate amounts owed to the Company’s drug substance manufacturer totaling $9,900, $8,100 for consultants and advisors to the Company, $6,900 in services as the Company commenced development of a data management system for clinical trial patient data, $9,300 for legal fees and $9,400 for communications, miscellaneous drug development and clinical trial expense. As of December 31, 2012, Current Liabilities included accounts payable $57,000 and accounts payable related party of $8,582, which amounts were subsequently paid in 2013.

XML

Related Party

9 Months Ended

Sep. 30, 2013

Related Party Transactions [Abstract]

Related Party

2. Related Party

Based on its stock ownership in the Company, MD Anderson Cancer Center meets the criteria to be deemed a related party of Bio-Path Holdings. For the quarters ending September 30, 2013 and 2012, MD Anderson related party research and development expense was $15,000 and $47,582, respectively. MD Anderson related party research and development expense for the quarter ending September 30, 2013 was comprised of MD Anderson clinical trial hospital expense of $15,000. As of September 30, 2013 accrued expense related party was $52,050 for MD Anderson clinical trial hospital expense and accrued license payments related party of $50,000 for past patent expenses (See Notes 4., 5. and 6.). For the quarter ending September 30, 2012 related party research and development expense consisted of $39,000 for expenses for treating patients in the Company’s clinical trial and $8,582 for patent expenses. As of September 30, 2012, the Company had accrued expense of $39,000 for clinical trial expense for the related party, $8,582 in related party accounts payable and $50,000 in accrued license payments payable due to the related party for past patent expenses for the Company’s Technology License. See Notes 5 and 6.

XML

Commitments and Contingencies - Additional Information (Detail) (USD $)	9 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Product Liability Contingency [Line Items]
Estimates reimbursable past patent expenses	$ 75,000
Patent expense per quarter	25,000
Accrued expense - related party	52,050
Other inventory, gross	148,301	195,000
Drug Product Testing Agreement Consideration To Be Paid In Stages	340,000
Technology Licenses
Product Liability Contingency [Line Items]
Accounts payable and accrued liabilities	$ 50,000

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Preferred Stock, par value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value	$ 0.001	$ 0.001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	75,380,214	62,219,050
Common Stock, shares outstanding	75,380,214	62,219,050
Additional paid in capital for shares to be issued, shares of common stock	8,052,416	2,541,700

XML

Additional Paid In Capital For Shares To Be Issued

9 Months Ended

Sep. 30, 2013

Shares To Be Issued [Abstract]

Additional Paid In Capital For Shares To Be Issued

7. Additional Paid In Capital For Shares To Be Issued

During 2012 the Company sold shares of common stock for cash to investors in a private placement. As of December 31, 2012, there were 2,541,700 shares of common stock remaining to be issued, representing $762,510 in sales to accredited investors. The Company has closed this offering at the end of the first quarter 2013 and subsequently issued the shares of common stock to these investors in the second quarter of 2013. During the third quarter of 2013 the Company sold shares of common stock for cash to investors in another private placement. As of September 30, 2013, there were 8,052,416 shares of common stock to be issued, representing $3,220,967 in sales to accredited investors. The Company closed this offering during September of 2013. 

XML

CONSOLIDATED STATEMENTS OF OPERATIONS (Parenthetical) (USD $)	3 Months Ended		9 Months Ended		77 Months Ended	3 Months Ended	9 Months Ended		77 Months Ended
	Sep. 30, 2013 Research and Development Expense	Sep. 30, 2012 Research and Development Expense	Sep. 30, 2013 Research and Development Expense	Sep. 30, 2012 Research and Development Expense	Sep. 30, 2013 Research and Development Expense	Sep. 30, 2013 General and Administrative Expense	Sep. 30, 2013 General and Administrative Expense	Sep. 30, 2012 General and Administrative Expense	Sep. 30, 2013 General and Administrative Expense
Equity compensation	$ 6,623	$ 11,414	$ 26,256	$ 42,231	$ 449,255
Amortization expenses	40,156	48,503	120,469	145,115	1,097,203
Stock option and warrant expense						599,424	609,347	3,250	3,200,103
Stock for services									318,500
Technology impairment charge				$ 345,000	$ 690,000

XML

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2013		Dec. 31, 2012
Current assets
Cash	$ 4,100,841		$ 534,046
Prepaid drug product for testing	148,301		195,000
Other current assets	49,713		42,575
Total current assets	4,298,855		771,621
Other assets
Technology licenses - related party	2,500,374		2,500,374
Less Accumulated Amortization	(1,048,700)		(928,231)
Intangible Assets, Net (Excluding Goodwill), Total	1,451,674		1,572,143
TOTAL ASSETS	5,750,529		2,343,764
Current liabilities
Accounts payable	43,578		57,000
Accounts payable - related party	0		8,582
Accrued expense	28,125		137,662
Accrued expense - related party	52,050		26,000
Accrued license payments - related party	50,000		100,000
Total current liabilities	173,753		329,244
Long term debt	0		0
TOTAL LIABILITIES	173,753		329,244
Shareholders' Equity
Preferred Stock, $.001 par value 10,000,000 shares authorized, no shares issued and outstanding	0		0
Common Stock, $.001 par value, 200,000,000 shares authorized 75,380,214 and 62,219,050 shares issued and outstanding as of 9/30/13 and 12/31/12, respectively	75,380		62,218
Additional paid in capital	16,888,167		13,321,075
Additional paid in capital for shares to be issued	3,220,967	[1]	762,510	[2]
Accumulated deficit during development stage	(14,607,738)		(12,131,283)
Total shareholders' equity	5,576,776		2,014,520
TOTAL LIABILITIES & SHAREHOLDERS' EQUITY	$ 5,750,529		$ 2,343,764

[1] Represents 8,052,416 shares of common stock

[2] Represents 2,541,700 shares of common stock

XML

Subsequent Events - Additional Information (Detail) (Subsequent Event, USD $) In Millions, except Share data, unless otherwise specified	1 Months Ended	9 Months Ended
	Nov. 05, 2013	Sep. 30, 2013 Private Placement
Subsequent Event [Line Items]
Stock issued during period shares other		8,052,416
Stock issued during period shares new issues		805,242
Sale of securities consideration received on transaction	$ 100

XML

Accrued Expense - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expense	$ 28,125	$ 137,662
Accrued expense - related party	$ 52,050	$ 26,000

XML

Accrued License Payments - Related Party

9 Months Ended

Sep. 30, 2013

Accrued License Payment Related Party [Abstract]

Accrued License Payments - Related Party

6. Accrued License Payments – Related Party

Accrued license payments related party totaling $50,000 and $100,000 were included in Current Liabilities as of September 30, 2013 and December 31, 2012, respectively. The amount included for September 30, 2013 represents reimbursement of past patent expenses incurred by MD Anderson prior to the Bio-Path license.

XML

Stock Options and Warrants

9 Months Ended

Sep. 30, 2013

Stock Options and Warrants [Abstract]

Stock Options and Warrants

9. Stock Options and Warrants

Stock Option - In August of 2013 the Company made stock option grants to management and officers to purchase in the aggregate 2,500,000 shares of the Company’s common stock. The previous grant of stock options to management and officers was made in 2008. Terms of the stock option grants require that the individuals continue employment with the Company over the vesting period of the option, fifty percent (50%) of which vested upon the date of the grant of the stock options and fifty percent (50%) of which will vest over 3 years from the date that the options were granted. The exercise price of the option is $0.46 per share, which was the closing price of the common stock at the date of the grants being approved. The Company determined the fair value of the stock option granted using the Black Scholes model and expenses this value monthly based upon the vesting schedule of the stock option award. For purposes of determining fair value, the Company used an average annual volatility of one hundred eighty nine percent (189%), which was calculated based on the closing price of the Company’s stock over the preceding five years. The risk free rate of interest used in the model was taken from a table of the market rate of interest for U. S. Government Securities for the date of the stock option awards and the effective term. The Company used the simplified method to determine the expected term of the options due to the lack of historical data. The total value of stock options granted to management and officers was determined using this methodology to be $1,125,000, half of which was expensed at the date of grant and the balance will be expensed over the next three years based on the stock option service period.

Warrant -  There were no warrants for services granted during the quarter ending September 30, 2013.

XML

Accrued Expense

9 Months Ended

Sep. 30, 2013

Accrued Liabilities [Abstract]

Accrued Expense

5. Accrued Expense

As of September 30, 2013, Current Liabilities included accrued expense of $28,125 for clinical trial operations management and management bonus accrual. Current Liabilities as of September 30, 2013 also included accrued expense related party of $52,050 for MD Anderson clinical trial hospital expense. (See Note 2.). As of December 31, 2012, Current Liabilities included accrued expense of $137,662 and accrued expense related party of $26,000.

XML

Basis of Presentation

9 Months Ended

Sep. 30, 2013

Basis Of Presentation [Abstract]

Basis of Accounting

The accompanying interim financial statements have been prepared with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders’ equity in conformity with generally accepted accounting principles. In the opinion of management, all adjustments considered necessary for a fair presentation of the results of operations and financial position have been included and all such adjustments are of a normal recurring nature. The unaudited quarterly financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Annual Report on Form 10-K of Bio-Path Holdings, Inc. (together with its subsidiary, “Bio-Path” or the “Company”) as of and for the fiscal year ended December 31, 2012. The results of operations for the period ended September 30, 2013, are not necessarily indicative of the results for a full-year period.

XML

Organization and Business - Additional Information (Detail) (USD $)	1 Months Ended	3 Months Ended	9 Months Ended		12 Months Ended	77 Months Ended
	Jun. 30, 2012	Sep. 30, 2013	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2011	Sep. 30, 2013	Dec. 31, 2012	May 09, 2007
Organization and Nature of Operations [Line Items]
Percentage of Charge					50.00%
Impairment of License			$ 0	$ 345,000	$ 345,000	$ 690,000
Cash		4,100,841	4,100,841	332,862	952,252	4,100,841	534,046	0
Carrying value of the siRNA license	345,000
Placement agent commission		$ 2,800,000
Phase I clinical trial
Organization and Nature of Operations [Line Items]
Number patients benefited from Liposomal Grb-2 treatment		3	3			3

XML

Stockholders' Equity

9 Months Ended

Sep. 30, 2013

Stockholders' Equity Note [Abstract]

Stockholders' Equity

8. Stockholders’ Equity

Issuance of Common Stock – In May and June of 2007, the Company issued 6,505,994 shares of common stock for $6,506 in cash to founders of the Company. In August of 2007, the Company issued 3,975,000 shares of common stock for $993,750 in cash to investors in the Company pursuant to a private placement memorandum. In August of 2007 the Company issued an additional 1,333,334 shares of common stock for $1,000,000 in cash to investors in the Company pursuant to a second round of financing. The Company issued 530,833 in common stock to the Placement Agent as commission for the shares of common stock sold to investors. In November of 2007, the Company issued 3,138,889 shares in common stock to MD Anderson as partial consideration for its two technology licenses from MD Anderson.

In February of 2008, the Company completed a reverse merger with Ogden Golf Co. Corporation and issued 38,023,578 shares of common stock of the public company Bio-Path Holdings (formerly Ogden Golf Co. Corporation) in exchange for pre-merger common stock of Bio-Path, Inc. In addition, shareholders of Ogden Golf Co. Corporation retained 3,600,000 shares of common stock of Bio-Path Holdings. In February of 2008 Bio-Path issued 80,000 shares of common stock to strategic consultants pursuant to executed agreements and the fair value was expensed upfront as common stock for services. In April of 2008, the Company issued 200,000 shares of common stock to a firm in connection with introducing Bio-Path, Inc. to its merger partner Ogden Golf Co. Corporation. The fair value of this stock issuance was expensed upfront as common stock for services valued at $180,000. In April of 2008, the Company recorded an additional 24 shares for rounding in accordance with FINRA rules. In December of 2008, the Company issued 100,000 shares of common stock to an investor relations firm for services. The fair value of this stock issuance was expensed upfront as common stock for services valued at $40,000. There were no issuances of shares during the first quarter of 2009. In June of 2009, the Company issued 660,000 shares of common stock and warrants to purchase an additional 660,000 shares of common stock for $165,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 66,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. There were no issuances of shares during the fourth quarter of 2009.

In November and December of 2009, the Company sold shares of common stock and warrants to purchase shares of common stock for $675,000 in cash to investors pursuant to a private placement memorandum. These shares were not issued by the December 31, 2009 year end. In January 2010, the Company issued these investors 2,700,000 shares of common stock and warrants to purchase an additional 2,700,000 shares of common stock. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In January 2010, the Company also sold an additional 900,000 shares of common stock and warrants to purchase an additional 900,000 shares of common stock for $225,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance and the exercise price is $1.50 a share. In connection with these private placement sales of equity, the Company issued 360,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In May of 2010, the Company issued 780,000 shares of common stock and warrants to purchase an additional 780,000 shares of common stock for $273,000 in cash to investors in the Company pursuant to a private placement memorandum. The warrants must be exercised within two years from the date of issuance. The exercise price of the warrants is $1.50 a share. In connection with this private placement, the Company issued 78,000 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors.

In June of 2010, the Company signed an equity purchase agreement for up to $7 million with Lincoln Park Capital Fund, LLC (“LPC” or “Lincoln”), a Chicago-based institutional investor. Under the terms of the equity purchase agreement, the Company has the right to sell shares of its common stock to LPC from time to time over a 24-month period in amounts between $50,000 and $1,000,000 up to an aggregate amount of $7 million depending upon certain conditions set forth in the purchase agreement including that a registration statement related to the transaction has been declared effective by the U.S. Securities and Exchange Commission (“SEC”). As a result, a registration statement was filed and later declared effective by the SEC on July 12, 2010. Upon signing the agreement, the Company received $200,000 from LPC as an initial purchase in exchange for 571,429 shares (“Initial Purchase Shares”) of the Company’s common stock and warrants to purchase 571,429 shares of the Company’s common stock at an exercise price of $1.50 per share. Subsequent purchases of the Company’s common stock by Lincoln Park under the agreement do not include warrants. In connection with the signing of the LPC financing agreement, the Company issued LPC 12,000 shares of the Company’s common stock for its due diligence efforts and 566,801 shares of the Company’s common stock as a commitment fee for the balance of the $7 million equity purchase commitment.

In July of 2010, the Company received $150,000 from LPC in exchange for 375,000 shares of the Company’s common stock. LPC was also issued 6,251 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 375,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In September of 2010, the Company received $50,000 from LPC in exchange for 125,000 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 125,000 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In November of 2010, the Company received $50,000 from LPC in exchange for 135,135 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 135,135 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

From November 2010 through April of 2011 the Company sold shares of common stock for $1,794,205 in cash to investors pursuant to a private placement memorandum. In June of 2011, the Company issued 5,980,685 shares of common stock to these investors. In connection with this private placement, in June of 2011 the Company issued 598,069 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors in connection with the sale of the common stock.

In June of 2011, the Company received $50,000 from LPC in exchange for 164,853 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 164,853 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In October of 2011, the Company issued 1,920,000 shares of common stock for $576,000 to investors who exercised warrants from September to October 2011.

In November of 2011, the Company received $25,000 from LPC in exchange for 83,333 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 83,333 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In December of 2011, the Company received $50,000 from LPC in exchange for 172,414 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 172,414 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In March of 2012, the Company received $50,000 from LPC in exchange for 166,667 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 166,667 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In April of 2012, LPC made three separate purchases of the Company’s common stock. The Company received $25,000 from LPC in exchange for 89,286 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 89,286 shares of common stock. The Company received another $25,000 from LPC in exchange for 96,154 shares of the Company’s common stock. LPC was also issued 1,042 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 96,154 shares of common stock. Finally, the Company received $50,000 from LPC in exchange for 185,185 shares of the Company’s common stock. LPC was also issued 2,084 shares of the Company’s common stock as a commitment fee in connection with the purchase of the 185,185 shares of common stock. No warrants to purchase additional shares of common stock of the Company were issued to Lincoln in connection with the sale of the common stock.

In June of 2012, the Company sold $150,000 in shares of its common stock pursuant to a private placement, with shares to be issued, and $18,500 in shares of its common stock for services with shares to be issued.

In August of 2012, the Company issued 50,000 shares of its common stock for the $18,500 shares for services previously recognized in June 2012.

In July through September of 2012, the Company sold $795,001 in shares of its common stock pursuant to a private placement, with shares to be issued.

In October through December of 2012, the Company sold $708,600 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of December 31, 2012 the Company issued 3,300,337 shares of its common stock to investors who purchased shares of common stock from the period June through September of 2012.

In February and March of 2013, the Company sold $346,201 in shares of its common stock pursuant to a private placement, with shares to be issued.

In April and May of 2013, the Company sold $2,000,198 in shares of its common stock pursuant to a private placement, with shares to be issued, and $489,501 in shares of its common stock pursuant in a direct offering, with shares to be issued.

In June of 2013, the Company issued 11,664,665 shares of common stock to investors in connection with the private placement and direct offering. In June of 2013 the Company issued 1,496,499 shares of common stock to the Placement Agent as commission for the shares of common stock sold to investors. No warrants to purchase additional shares of common stock of the Company were issued to these investors or to the Placement Agent in connection with the sale of the common stock.

In August and September of 2013, the Company sold $3,220,966 in shares of its common stock pursuant to a private placement, with shares to be issued.

As of September 30, 2013, there were 75,380,214 shares of common stock issued and outstanding. There are no preferred shares outstanding as of September 30, 2013.

XML

Accounts Payable - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Accounts Payable [Line Items]
Accounts payable	$ 43,578	$ 57,000
Accounts payable, other, current	6,900
Accounts payable - related party	0	8,582	8,582
Accounts payable to communication expenses	9,400
Accounts payable to legal fees current	9,300
Consultants
Accounts Payable [Line Items]
Accounts payable, trade	9,900
Advisors
Accounts Payable [Line Items]
Accounts payable, trade	$ 8,100

XML

Related Party - Additional Information (Detail) (USD $)				3 Months Ended
	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2012 MD Anderson Cancer Center	Sep. 30, 2013 MD Anderson Cancer Center Clinical Trials	Sep. 30, 2012 MD Anderson Cancer Center Clinical Trials	Sep. 30, 2013 MD Anderson Cancer Center Research and Development Expense	Sep. 30, 2012 MD Anderson Cancer Center Research and Development Expense
Related Party Transaction [Line Items]
Accrued expense - related party	$ 52,050	$ 26,000		$ 50,000	$ 52,050	$ 39,000
Accrued license payments - related party	50,000	100,000
Cash paid to MD Anderson Cancer Center for expenses							15,000	47,582
Accounts payable - related party	0	8,582	8,582
Research and Development Expense					15,000	39,000
Patent Expense				$ 8,582

XML

Document And Entity Information	9 Months Ended
	Sep. 30, 2013	Nov. 12, 2013
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q3
Trading Symbol	BPTH
Entity Common Stock, Shares Outstanding		84,237,872
Entity Registrant Name	BIO-PATH HOLDINGS INC
Entity Central Index Key	0001133818
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company

XML

Prepaid Drug Product for Testing - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012
Inventory Disclosure [Line Items]
Prepaid drug product for testing	$ 148,301	$ 195,000